Associated Papers
Prevalence of Atypical and Subclonal p53 Immunohistochemistry Expression in Mismatch Repair Deficient and/or POLE-Mutant Endometrial Carcinomas with TP53 Mutation.
Wang J et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 2025
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1.
Mur P et al.
Genome Medicine, 2023
37848928 (PubMed )
Supplement: 13073_2023_1234_MOESM3_ESM.xlsx › Table_S3
Potential genetic biomarker of Saudi Arabian patients with colorectal cancer.
Younis NS et al.
European Review for Medical and Pharmacological Sciences, 2022
Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data.
Jiang M et al.
Frontiers in Genetics, 2022
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
Magrin L et al.
Oncogene, 2021
POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
Siraj AK et al.
Molecular Genetics & Genomic Medicine, 2020
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D et al.
The Journal of Pathology, 2018
29604063 (PubMed )
Supplement: PATH-245-283-s020.xlsx › Figure.2.Drivers.Edited
Select a paper to view details